Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts.

Isaksson K, Nielsen K, Mikiver R, Nieweg OE, Scolyer RA, Thompson JF, Ingvar C.

J Surg Oncol. 2018 Sep 9. doi: 10.1002/jso.25208. [Epub ahead of print]

PMID:
30196533
2.

Endogenous expression mapping of malignant melanoma by mass spectrometry imaging.

Sugihara Y, Rivas D, Malm J, Szasz M, Kwon H, Baldetorp B, Olsson H, Ingvar C, Rezeli M, Fehniger TE, Marko-Varga G.

Clin Transl Med. 2018 Aug 6;7(1):22. doi: 10.1186/s40169-018-0201-x.

3.

Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment.

Björner S, Rosendahl AH, Tryggvadottir H, Simonsson M, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H.

Front Endocrinol (Lausanne). 2018 Jun 6;9:306. doi: 10.3389/fendo.2018.00306. eCollection 2018.

4.

Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis.

Wisse A, Tryggvadottir H, Simonsson M, Isaksson K, Rose C, Ingvar C, Jernström H.

Cancer Causes Control. 2018 Jul;29(7):643-656. doi: 10.1007/s10552-018-1042-z. Epub 2018 May 26.

5.

Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer.

Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H.

Front Endocrinol (Lausanne). 2017 Nov 28;8:332. doi: 10.3389/fendo.2017.00332. eCollection 2017.

6.

Benefits of initial CT staging before sentinel lymph node biopsy in patients with head and neck cutaneous melanoma.

Hafström A, Silfverschiöld M, Persson SS, Kanne M, Ingvar C, Wahlberg P, Romell A, Greiff L.

Head Neck. 2017 Nov;39(11):2301-2310. doi: 10.1002/hed.24901. Epub 2017 Aug 21.

PMID:
28833785
7.

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Taylor NJ, Mitra N, Goldstein AM, Tucker MA, Avril MF, Azizi E, Bergman W, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Grazziotin TC, Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard A, Puig S, van der Stoep N, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Study Group.

J Invest Dermatol. 2017 Dec;137(12):2606-2612. doi: 10.1016/j.jid.2017.07.829. Epub 2017 Aug 19.

8.

Combined Magnetomotive ultrasound, PET/CT, and MR imaging of 68Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo.

Evertsson M, Kjellman P, Cinthio M, Andersson R, Tran TA, In't Zandt R, Grafström G, Toftevall H, Fredriksson S, Ingvar C, Strand SE, Jansson T.

Sci Rep. 2017 Jul 6;7(1):4824. doi: 10.1038/s41598-017-04396-z.

9.

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM.

N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.

10.

Varannan timme får en svensk ett nytt malignt melanom - Incidens, utfall och prevention.

Ingvar C, Eriksson H.

Lakartidningen. 2017 May 9;114. pii: ELAT. Swedish.

11.

Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.

Welinder C, Pawłowski K, Szasz AM, Yakovleva M, Sugihara Y, Malm J, Jönsson G, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Rezeli M, Laurell T, Wieslander E, Marko-Varga G.

PLoS One. 2017 Apr 26;12(4):e0176167. doi: 10.1371/journal.pone.0176167. eCollection 2017.

12.

Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register.

Lyth J, Falk M, Maroti M, Eriksson H, Ingvar C.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1468-1474. doi: 10.1111/jdv.14280. Epub 2017 May 9.

PMID:
28419674
13.

NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.

Cirenajwis H, Lauss M, Ekedahl H, Törngren T, Kvist A, Saal LH, Olsson H, Staaf J, Carneiro A, Ingvar C, Harbst K, Hayward NK, Jönsson G.

Mol Oncol. 2017 Apr;11(4):438-451. doi: 10.1002/1878-0261.12050. Epub 2017 Mar 24.

14.

Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.

Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H.

Oncotarget. 2017 Feb 7;8(6):9093-9107. doi: 10.18632/oncotarget.14082.

15.

High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy-Treated Patients-Results from a Population-Based Breast Cancer Cohort.

Elebro K, Borgquist S, Rosendahl AH, Markkula A, Simonsson M, Jirström K, Rose C, Ingvar C, Jernström H.

Clin Cancer Res. 2017 Feb 1;23(3):766-777. doi: 10.1158/1078-0432.CCR-16-1095. Epub 2016 Nov 3.

16.

The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.

Simonsson M, Björner S, Markkula A, Nodin B, Jirström K, Rose C, Borgquist S, Ingvar C, Jernström H.

Int J Cancer. 2017 Jan 1;140(1):163-175. doi: 10.1002/ijc.30432. Epub 2016 Sep 28.

17.

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.

Yang XR, Rotunno M, Xiao Y, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Bennett H, Graham C, Sampson JN, Malasky M, Vogt A, Zhu B, Bianchi-Scarra G, Bruno W, Queirolo P, Fornarini G, Hansson J, Tuominen R, Burdett L, Hicks B, Hutchinson A, Jones K, Yeager M, Chanock SJ, Landi MT, Höiom V, Olsson H, Gruis N, Ghiorzo P, Tucker MA, Goldstein AM.

Hum Genet. 2016 Nov;135(11):1241-1249. Epub 2016 Jul 23.

18.

High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma.

Ekedahl H, Lauss M, Olsson H, Griewank KG, Schadendorf D, Ingvar C, Jönsson G.

Pigment Cell Melanoma Res. 2016 Sep;29(5):598-600. doi: 10.1111/pcmr.12500. Epub 2016 Aug 1. No abstract available.

PMID:
27301352
19.

Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.

Persson M, Simonsson M, Markkula A, Rose C, Ingvar C, Jernström H.

Br J Cancer. 2016 Jul 26;115(3):382-90. doi: 10.1038/bjc.2016.174. Epub 2016 Jun 9.

20.

Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma.

Harbst K, Lauss M, Cirenajwis H, Isaksson K, Rosengren F, Törngren T, Kvist A, Johansson MC, Vallon-Christersson J, Baldetorp B, Borg Å, Olsson H, Ingvar C, Carneiro A, Jönsson G.

Cancer Res. 2016 Aug 15;76(16):4765-74. doi: 10.1158/0008-5472.CAN-15-3476. Epub 2016 May 23.

21.
22.

Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register.

Lyth J, Mikiver R, Nielsen K, Isaksson K, Ingvar C.

Eur J Cancer. 2016 May;59:171-178. doi: 10.1016/j.ejca.2016.02.029. Epub 2016 Apr 2.

23.

CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.

Simonsson M, Veerla S, Markkula A, Rose C, Ingvar C, Jernström H.

BMC Cancer. 2016 Mar 31;16:256. doi: 10.1186/s12885-016-2284-3.

24.

Avoidance of sun exposure as a risk factor for major causes of death: a competing risk analysis of the Melanoma in Southern Sweden cohort.

Lindqvist PG, Epstein E, Nielsen K, Landin-Olsson M, Ingvar C, Olsson H.

J Intern Med. 2016 Oct;280(4):375-87. doi: 10.1111/joim.12496. Epub 2016 Mar 16.

PMID:
26992108
25.

Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.

Taylor NJ, Handorf EA, Mitra N, Avril MF, Azizi E, Bergman W, Bianchi-Scarrà G, Bishop DT, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Friedman E, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Hansson J, Hayward NK, Hocevar M, Höiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer J, Perić B, Pjanova D, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KA, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Consortium.

J Invest Dermatol. 2016 May;136(5):1066-9. doi: 10.1016/j.jid.2016.01.009. Epub 2016 Jan 28. No abstract available.

26.

Sentinel lymph node biopsy staging for cutaneous malignant melanoma of the head and neck.

Hafström A, Romell A, Ingvar C, Wahlberg P, Greiff L.

Acta Otolaryngol. 2016;136(3):312-8. doi: 10.3109/00016489.2015.1113559. Epub 2016 Jan 15.

PMID:
26767628
27.

Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.

Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, Ingvar C, Vermeulen T, Whitehead KJ, Schmidt CW, Palmer JM, Symmons J, Gerdes AM, Jönsson G, Hayward NK.

Oncotarget. 2016 Jan 26;7(4):4624-31. doi: 10.18632/oncotarget.6614.

28.

Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study.

Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P.

Int J Cancer. 2016 May 1;138(9):2154-60. doi: 10.1002/ijc.29961. Epub 2016 Jan 18.

29.

Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P; French Familial Melanoma Study Group, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B.

Nature. 2016 Mar 3;531(7592):126. doi: 10.1038/nature16158. Epub 2015 Dec 2. No abstract available.

PMID:
26633630
30.

Long-term Follow-up After Interstitial Laser Thermotherapy of Breast Cancer.

Haraldsdóttir KH, Ingvar C, Stenram U, Tranberg KG.

Anticancer Res. 2015 Nov;35(11):6147-52.

PMID:
26504041
31.

Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma.

Law MH, Bishop DT, Lee JE, Brossard M, Martin NG, Moses EK, Song F, Barrett JH, Kumar R, Easton DF, Pharoah PDP, Swerdlow AJ, Kypreou KP, Taylor JC, Harland M, Randerson-Moor J, Akslen LA, Andresen PA, Avril MF, Azizi E, Scarrà GB, Brown KM, Dębniak T, Duffy DL, Elder DE, Fang S, Friedman E, Galan P, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Helsing P, Hočevar M, Höiom V, Ingvar C, Kanetsky PA, Chen WV; GenoMEL Consortium; Essen-Heidelberg Investigators; SDH Study Group; Q-MEGA and QTWIN Investigators; AMFS Investigators; ATHENS Melanoma Study Group, Landi MT, Lang J, Lathrop GM, Lubiński J, Mackie RM, Mann GJ, Molven A, Montgomery GW, Novaković S, Olsson H, Puig S, Puig-Butille JA, Qureshi AA, Radford-Smith GL, van der Stoep N, van Doorn R, Whiteman DC, Craig JE, Schadendorf D, Simms LA, Burdon KP, Nyholt DR, Pooley KA, Orr N, Stratigos AJ, Cust AE, Ward SV, Hayward NK, Han J, Schulze HJ, Dunning AM, Bishop JAN, Demenais F, Amos CI, MacGregor S, Iles MM.

Nat Genet. 2015 Sep;47(9):987-995. doi: 10.1038/ng.3373. Epub 2015 Aug 3.

32.

Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Gustbée E, Tryggvadottir H, Markkula A, Simonsson M, Nodin B, Jirström K, Rose C, Ingvar C, Borgquist S, Jernström H.

BMC Clin Pathol. 2015 May 20;15:8. doi: 10.1186/s12907-015-0008-2. eCollection 2015.

33.

Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

JAMA. 2015 Jun 23-30;313(24):2449-55. doi: 10.1001/jama.2015.6604.

PMID:
26103029
34.

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D, van Westen D, Fernö M, Ingvar C, Rose C, Bendahl PO, Rydén L, Borg Å, Gruvberger-Saal SK, Jernström H, Saal LH.

EMBO Mol Med. 2015 Aug;7(8):1034-47. doi: 10.15252/emmm.201404913.

35.

Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.

Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, Rosengren F, Werner-Hartman L, Törngren T, Kvist A, Fredlund E, Bendahl PO, Jirström K, Lundgren L, Howlin J, Borg Å, Gruvberger-Saal SK, Saal LH, Nielsen K, Ringnér M, Tsao H, Olsson H, Ingvar C, Staaf J, Jönsson G.

Oncotarget. 2015 May 20;6(14):12297-309.

36.

Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.

Elebro K, Borgquist S, Simonsson M, Markkula A, Jirström K, Ingvar C, Rose C, Jernström H.

Clin Cancer Res. 2015 Aug 15;21(16):3640-50. doi: 10.1158/1078-0432.CCR-14-2564. Epub 2015 Apr 22.

37.

A protein deep sequencing evaluation of metastatic melanoma tissues.

Welinder C, Pawłowski K, Sugihara Y, Yakovleva M, Jönsson G, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Rezeli M, Jansson B, Laurell T, Fehniger T, Döme B, Malm J, Wieslander E, Nishimura T, Marko-Varga G.

PLoS One. 2015 Apr 13;10(4):e0123661. doi: 10.1371/journal.pone.0123661. eCollection 2015.

38.

[Final reply from Hans Wingstrand and co-authors: Reintroduce confidentiality in IT systems].

Wingstrand H, Hanson B, Hjelmqvist B, Ingvar C.

Lakartidningen. 2015 Mar 16;112. pii: DEPL. Swedish. No abstract available.

39.

Development and validation of a melanoma risk score based on pooled data from 16 case-control studies.

Davies JR, Chang YM, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green A, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Lee TK, Le Marchand L, Mackie RM, Olsson H, Østerlind A, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus L, Zens MS, Ziegler A, Gallagher RP, Barrett JH, Newton-Bishop J.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):817-24. doi: 10.1158/1055-9965.EPI-14-1062. Epub 2015 Feb 24.

40.

Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer.

Rosendahl AH, Perks CM, Zeng L, Markkula A, Simonsson M, Rose C, Ingvar C, Holly JM, Jernström H.

Clin Cancer Res. 2015 Apr 15;21(8):1877-87. doi: 10.1158/1078-0432.CCR-14-1748. Epub 2015 Feb 17.

41.

History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response.

Huzell L, Persson M, Simonsson M, Markkula A, Ingvar C, Rose C, Jernström H.

Breast Cancer Res Treat. 2015 Jan;149(2):505-15. doi: 10.1007/s10549-014-3252-8. Epub 2015 Jan 4.

PMID:
25556354
42.

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.

Aoude LG, Pritchard AL, Robles-Espinoza CD, Wadt K, Harland M, Choi J, Gartside M, Quesada V, Johansson P, Palmer JM, Ramsay AJ, Zhang X, Jones K, Symmons J, Holland EA, Schmid H, Bonazzi V, Woods S, Dutton-Regester K, Stark MS, Snowden H, van Doorn R, Montgomery GW, Martin NG, Keane TM, López-Otín C, Gerdes AM, Olsson H, Ingvar C, Borg A, Gruis NA, Trent JM, Jönsson G, Bishop DT, Mann GJ, Newton-Bishop JA, Brown KM, Adams DJ, Hayward NK.

J Natl Cancer Inst. 2014 Dec 13;107(2). pii: dju408. doi: 10.1093/jnci/dju408. Print 2015 Feb.

43.

Analysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assay.

Welinder C, Jönsson GB, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Breslin T, Rezeli M, Jansson B, Fehniger TE, Laurell T, Wieslander E, Pawlowski K, Marko-Varga G.

PLoS One. 2014 Oct 21;9(10):e110804. doi: 10.1371/journal.pone.0110804. eCollection 2014.

44.

Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men.

Lyth J, Eriksson H, Hansson J, Ingvar C, Jansson M, Lapins J, Månsson-Brahme E, Naredi P, Stierner U, Ullenhag G, Carstensen J, Lindholm C.

Br J Dermatol. 2015 Mar;172(3):700-6. doi: 10.1111/bjd.13483. Epub 2015 Feb 5.

45.

IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.

Markkula A, Simonsson M, Ingvar C, Rose C, Jernström H.

BMC Cancer. 2014 Oct 11;14:759. doi: 10.1186/1471-2407-14-759.

46.

The effect on melanoma risk of genes previously associated with telomere length.

Iles MM, Bishop DT, Taylor JC, Hayward NK, Brossard M, Cust AE, Dunning AM, Lee JE, Moses EK, Akslen LA; AMFS Investigators, Andresen PA, Avril MF, Azizi E, Scarrà GB, Brown KM, Dębniak T, Elder DE, Friedman E, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Harland M, Helsing P, Hočevar M, Höiom V; IBD investigators, Ingvar C, Kanetsky PA, Landi MT, Lang J, Lathrop GM, Lubiński J, Mackie RM, Martin NG, Molven A, Montgomery GW, Novaković S, Olsson H, Puig S, Puig-Butille JA; QMEGA and QTWIN Investigators, Radford-Smith GL, Randerson-Moor J; SDH Study Group, van der Stoep N, van Doorn R, Whiteman DC, MacGregor S, Pooley KA, Ward SV, Mann GJ, Amos CI, Pharoah PD, Demenais F, Law MH, Newton Bishop JA, Barrett JH; GenoMEL Consortium.

J Natl Cancer Inst. 2014 Sep 17;106(10). pii: dju267. doi: 10.1093/jnci/dju267. Print 2014 Oct.

47.

The clinicopathological and gene expression patterns associated with ulceration of primary melanoma.

Jewell R, Elliott F, Laye J, Nsengimana J, Davies J, Walker C, Conway C, Mitra A, Harland M, Cook MG, Boon A, Storr S, Safuan S, Martin SG, Jirström K, Olsson H, Ingvar C, Lauss M, Bishop T, Jönsson G, Newton-Bishop J.

Pigment Cell Melanoma Res. 2015 Jan;28(1):94-104. doi: 10.1111/pcmr.12315. Epub 2014 Oct 1.

48.

Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions.

Barrett JH, Taylor JC, Bright C, Harland M, Dunning AM, Akslen LA, Andresen PA, Avril MF, Azizi E, Bianchi Scarrà G, Brossard M, Brown KM, Dębniak T, Elder DE, Friedman E, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Helsing P, Hočevar M, Höiom V, Ingvar C, Landi MT, Lang J, Lathrop GM, Lubiński J, Mackie RM, Molven A, Novaković S, Olsson H, Puig S, Puig-Butille JA, van der Stoep N, van Doorn R, van Workum W, Goldstein AM, Kanetsky PA, Pharoah PD, Demenais F, Hayward NK, Newton Bishop JA, Bishop DT, Iles MM; GenoMEL Consortium.

Int J Cancer. 2015 Mar 15;136(6):1351-60. doi: 10.1002/ijc.29099. Epub 2014 Aug 14.

49.

A new look at drugs targeting malignant melanoma--an application for mass spectrometry imaging.

Sugihara Y, Végvári A, Welinder C, Jönsson G, Ingvar C, Lundgren L, Olsson H, Breslin T, Wieslander E, Laurell T, Rezeli M, Jansson B, Nishimura T, Fehniger TE, Baldetorp B, Marko-Varga G.

Proteomics. 2014 Sep;14(17-18):1963-70. doi: 10.1002/pmic.201300476. Epub 2014 Aug 18. Review.

PMID:
25044963
50.

Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Staaf J, Harbst K, Lauss M, Ringnér M, Måsbäck A, Howlin J, Jirström K, Harland M, Zebary A, Palmer JM, Ingvar C, Olsson H, Newton-Bishop J, Hansson J, Hayward N, Gruis N, Jönsson G.

J Invest Dermatol. 2014 Dec;134(12):3000-3003. doi: 10.1038/jid.2014.272. Epub 2014 Jul 7. No abstract available.

Supplemental Content

Loading ...
Support Center